BACKGROUND AND TOPICS FOR DISCUSSION:

America's biomedical research enterprise is navigating significant upheaval as traditional funding models face political and economic disruptions. While government funding encounters new constraints and uncertainties, this challenging period is also revealing alternative pathways for translating discoveries into medical breakthroughs.

This panel examines fundamental questions reshaping how academic and government discoveries become patient treatments: Must universities reimagine their business models in response to funding pressures? How do we balance academic and scientific independence? What new institutional models might emerge as traditional pathways face uncertainty? Do recent successes represent a new template for rapid translation?

Leaders will examine evolving roles of private foundations, venture capital, and international partnerships in addressing gaps within the research ecosystem.

Central to these discussions is the tension between public investment and private returns, maintaining scientific leadership amid global competition, and whether current translation systems can deliver needed medical innovations. This panel brings together leaders to explore emerging models as academic-government-industry partnerships adapt to increasingly complex conditions.

BACKGROUND AND TOPICS FOR DISCUSSION:

This fireside chat explores how the life sciences industry can navigate unprecedented complexity while seizing transformational opportunities. As global health challenges intensify and industry headwinds multiply, leaders must balance immediate pressures with long-term innovation potential.

The conversation addresses fundamental questions shaping the industry's future: How do we frame this moment of simultaneous challenge and opportunity? Can breakthrough approaches in one therapeutic area become blueprints for broader transformation? What does it take to maintain innovation leadership in an increasingly competitive global landscape?

The discussion examines critical ecosystem questions about preserving competitive advantages, attracting talent, and building resilient partnerships that can withstand geopolitical and economic pressures. How do we balance domestic priorities with the inherently collaborative nature of modern innovation?

The conversation concludes with personal perspectives on leadership during periods of transformation. Drawing from Bourla's unique background and experience, the discussion explores how diverse perspectives and personal resilience inform the type of visionary leadership needed to guide complex organizations through uncertainty while maintaining focus on patient impact and scientific advancement.

BACKGROUND AND TOPICS FOR DISCUSSION:

Neurodegenerative diseases—including Alzheimer’s, Parkinson’s, ALS, and others—pose someof the most formidable challenges in biomedical research and drug development. Characterizedby complex pathophysiology, limited biomarkers, and historically high clinical trial failure rates,these disorders demand new paradigms in therapeutic innovation.

This panel will explore thescientific advances reshaping our understanding of neurodegeneration — from novel targetsand disease-modifying strategies to the integration of AI, multi-omics, and translationalneuroscience – as well as the emerging therapeutic modalities in development to moreeffectively treat these devastating diseases.

We will also examine the profound economic,emotional, and societal toll these diseases exact on patients, caregivers, and healthcaresystems—and discuss how the next generation of treatments could alter that trajectory.

BACKGROUND AND TOPICS FOR DISCUSSION:

How do scientific breakthroughs reshape entire therapeutic categories? This panel explores the development of dupilumab, a fully human monoclonal antibody, as a lens through which to examine broader questions about modern biologic drug development.

Panelists will explore the underlying decisions and discoveries that transformed the treatment landscape for diseases with underlying type 2 inflammation. Topics include the evolution from broad immunosuppression to targeted pathway inhibition, the role of platform technologies in accelerating development timelines, and considerations involved in demonstrating efficacy across diverse patient populations. The session will address such key questions as: How do you identify truly paradigm-shifting approaches? What does it take to build evidence for novel mechanisms? What can we learn from the development of innovative approaches?